Chemenu

Nocion Therapeutics presents data on preclinical and clinical development of Taplucainium, a novel, charged sodium channel blocker, as a potential treatment for chronic cough at the 13th London International Cough Symposium. Taplucainium is a proprietary molecule in the novel class of charged sodium channel blockers that allows for specific silencing of activated/inflamed nociceptors while having minimal local off-target effects or systemic exposure. Unlike other investigative cough therapies, such as P2X3-antagonists, TRPA1-antagonists and TRPM8-agonists, which target a specific large pore channel, taplucainium works downstream by selectively targeting the sodium channels in activated nociceptors which are the target of these large pore channels. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/gEwmsx7m Keywords: Taplucainium; NTX-1175; sodium channel blocker; building blocks  

Calico’s and AbbVie’s orally bioavailable eIF2B activator prodrug ABBV-CLS-7262 (fosigotifator) is being developed as a potential treatment for Vanishing White Matter disease (VWM), an ultra-rare progressive leukoencephalopathy. Accepted into the FDA’s START Pilot Program, ABBV-CLS-7262 is currently in an open-label Ph. I/II trial for adults and pediatrics with VWM disease and a randomized, double-blind Ph. I trial in patients with Amyotrophic Lateral Sclerosis (ALS). Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/gcCuFwAZ # ABBV-CLS-7262 # Fosigotifator # eIF2B # VWM # ALS # Chemenu # building blocks

Kronos Bio announces the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer (HGSOC). Many cancers exhibit transcriptional deregulation, often characterized by gene amplifications of MYC family oncogene. Targeting the transcription elongation cofactor, cyclin-dependent kinase 9 (CDK9) has emerged as a therapeutic strategy to disrupt MYC oncogenic activity. KB-0742 is an oral highly selective CDK9 inhibitor designed for the treatment of patients with MYC-amplified and other transcriptionally addicted relapsed or refractory solid tumors, including ovarian, lung, and triple-negative breast cancers. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/gHzCZpGb #MYC #tumors #ovariancancer #OC #HGSOC #CDK9 #inhibitor #buildingblocks #chemenu

Sumitomo Pharma announces that DSP-5336 has received FDA Fast Track Designation for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a KMT2A rearrangement, also known as, mixed lineage leukemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m). Menin serves as a tumor suppressor in endocrine glands. Novel menin inhibitors are novel targeted agents in clinical studies targeting genetically defined subsets of acute leukemia. DSP-5336 is an investigational menin-MLL interaction inhibitor. DSP-5336 has been granted Orphan Drug Designation in acute myeloid leukemia, and Fast Track Designation in relapsed or refractory acute myeloid leukemia with MLLr or NPM1m. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/g4ScXr8A #Menin #inhibitor #AML #KMT2A #MLLr #NPN1  #ALL #clinical #Leukemia #Chemenu

Bayer announced that its Phase 3 clinical ARANOTE trial met its primary endpoint. Its oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) combined with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA® (darolutamide) is an oral androgen receptor inhibitor with a distinct chemical structure that binds to androgen receptors with high affinity and exhibits strong antagonistic activity, thereby inhibiting receptor function and the growth of prostate cancer cells. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/gjqHGjDw # Darolutamide # NUBEQA # AR # ADT # mHSPC # Chemenu # building blocks

60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients. The FDA has granted its investigational tafenoquine candidate orphan drug designation for the treatment of patients with acute babesiosis. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA and in Australia as KODATEF. It is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/gWMngrRB  #Tafenoquine; #anti-malarial; #babesiosis; #building blocks  

The Journal of Medicinal Chemistry recently publishes an article titled, “Structure–Activity Relationship Studies of Aryl Sulfoxides as Reversible Monoacylglycerol Lipase Inhibitors”. Monoacylglycerol lipase (MAGL) is the critical enzyme responsible for the hydrolysis of endocannabinoid 2-arachidonoylglycerol (2-AG) to arachidonate and glycerol, contributing to the inflammatory cascade in the CNS. MAGL inhibition provides various potential therapeutic opportunities, including inflammation-induced tissue injury, pain, multiple sclerosis, and cancer. LEI-515 is an aryl sulfoxide, and a peripherally restricted, covalent reversible MAGL inhibitor. LEI-515 increases 2-AG levels in the periphery and reduces neuropathic pain and inflammation, without inducing CNS adverse effects or physical dependence. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/dpdydifw #MAGL #enzyme #hydrolysis #2-AG #2-arachidonoylglycerol #Inhibitor #inflammation #Drugdiscovery

Novartis’ HRO761 is an oral allosteric inhibitor targeting WRN helicase, aimed at treating microsatellite instability (MSI) or deficient mismatch repair (dMMR) tumors. WRN has emerged as a critical synthetic lethal target in MSI cancers, which are common in colorectal, gastric, endometrial, and ovarian cancers. Although MSI cancers show a high response rate to immune checkpoint inhibitors, many patients develop resistance. By acting on WRN, HRO761 may be able to stop the growth of the cancer. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/dwnCp6GA #HRO761 #WRN #MSI #dMMR #ColorectalCancer #Chemenu #buildingblocks

Sunobinop is an investigational, novel and potential first-in-class oral compound discovered by Imbrium Therapeutics and that is currently in clinical development. Sunobinop is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions, including bladder function. As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia. Chemenu has been working to develop more compounds for drug discovery. Here comes the building blocks we can provide: https://lnkd.in/dFTR63jy #Sunobinop #nociceptin #orphanin-FQ #NOP #S117957 #buildingblocks

Meet our team at Pharma ChemOutsourcing in Parsippany Hilton, NJ from September 3-6. We’re ready to talk with you at Space 30 how our R&D service can help. #research #process #drugdevelopment #smallmolecule #intermediate #materials